NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
Clinical Trials
6 trialsNCT05645718 2025-10-07
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02000427 2024-05-28
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2 Completed
NCT01207388 2020-02-10
BLAST
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT01466179 2017-08-18
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT01209286 2017-03-06
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
Phase 2 Completed